The research report from Western Securities points out that with the dual drivers of healthcare and consumption, Winner Medical is stabilizing and entering a growth year. In 2024, the company will launch an equity incentive plan, intending to grant 7.476 million restricted shares, accounting for approximately 1.28% of the company's total share capital. The performance assessment targets are that from 2025 to 2027, the revenue growth rate at the company level and for the two major business segments should not be less than 13% or 18% year-on-year, demonstrating the company's confidence in long-term development. Considering that the base of the company's medical consumables segment is returning to normal, the brand strength of consumer goods is prominent, and growth is driven by both internal and external factors, the rating is maintained at "Buy."